Xeris Biopharma Holdings, Inc.: directors' dealings · United States · SEC (Form 4)

About Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc. is a U.S.-based biopharmaceutical company listed on the Nasdaq stock market in the United States, with its principal office in Chicago, Illinois. From an equity-research perspective, Xeris is best understood as a commercial-stage specialty pharma platform rather than a pure early-stage biotech. The company focuses on developing, manufacturing, and commercializing differentiated therapies, supported by proprietary formulation technology designed to improve the usability of injectable medicines. Its platform, XeriSol/XeriJect, is intended to enable convenient delivery formats for selected compounds, which is strategically important in niche endocrinology and rare-disease markets. ([xerispharma.com](https://www.xerispharma.com/investor-relations/?utm_source=openai)) The company’s origins are tied to the broader wave of U.S. specialty biopharma innovation, and its current shape reflects both internal product development and corporate expansion. A key step in its evolution was the acquisition of Strongbridge, which broadened Xeris’s commercial footprint and strengthened its presence in specialty endocrine and rare-disease therapeutics. Today, the business is organized around three main commercial franchises: Gvoke, a ready-to-use glucagon for severe hypoglycemia; Recorlev (levoketoconazole), indicated for endogenous hypercortisolemia in adults with Cushing’s syndrome when surgery is not an option or has not been curative; and Keveyis (dichlorphenamide), used to treat primary periodic paralysis. Xeris also commercializes Ogluo in selected non-U.S. markets through a partnership arrangement. ([xerispharma.com](https://www.xerispharma.com/products?mobile=1&utm_source=openai)) In competitive terms, Xeris occupies a focused but attractive niche. Its portfolio targets clearly defined clinical needs, creating meaningful regulatory and commercial barriers to entry. Gvoke benefits from demand in the emergency glucagon category, while Recorlev has been the standout growth driver recently, helped by increasing numbers of patients on therapy. Keveyis is a more mature asset and contributes a steadier base of revenue, though with slower growth. As a result, Xeris has a profile that combines specialty pharma execution, rare-disease exposure, and commercial growth leverage. ([xerispharma.com](https://xerispharma.com/news-releases/news-release-details/xeris-biopharma-posts-record-financial-results-third-quarter?utm_source=openai)) Geographically, the company remains heavily U.S.-centric, with its core operating and commercial infrastructure in the United States, while maintaining more limited international reach through Ogluo in Europe and other covered territories. Recent developments have been notably positive on the operating side: in 2026, Xeris reported record full-year 2025 results, with total revenue of $292 million, and provided 2026 revenue guidance of $375 million to $390 million. The company also announced a patent-infringement lawsuit related to Recorlev in early 2026, a reminder that exclusivity protection is a material strategic issue for specialty pharma companies. ([ir.xerispharma.com](https://ir.xerispharma.com/news-releases/news-release-details/xeris-biopharma-reports-record-performance-fourth-quarter-and?utm_source=openai))